DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Gemcitabine Hydrochloride is a drug marketed by Accord Hlthcare, Actavis Inc, Actavis Totowa, Am Regent, Apotex, Cipla, Dr Reddys Labs Ltd, Emcure Pharms Ltd, Fresenius Kabi Usa, Gland Pharma Ltd, Hameln Rds Gmbh, Hikma Intl Pharms, Hospira, Hospira Inc, Jiangsu Hansoh Pharm, Meitheal, Mylan Labs Ltd, Novast Labs, Sagent Pharms, Sagent Pharms Inc, Shilpa, Sun Pharm, and Teva Pharms. and is included in twenty-nine NDAs.
The generic ingredient in GEMCITABINE HYDROCHLORIDE is gemcitabine hydrochloride. There are thirty drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the gemcitabine hydrochloride profile page.
A generic version of GEMCITABINE HYDROCHLORIDE was approved as gemcitabine hydrochloride by HOSPIRA INC on November 15th, 2010.
Recent Clinical Trials for GEMCITABINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
|University of Bern||Phase 2|
|3D Medicines (Sichuan) Co., Ltd.||Phase 2|
|Hospital Centre Biel/Bienne||Phase 2|